Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07107529Phase 2Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Role: collaborator

NCT03896737Phase 2Active Not Recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Role: collaborator

NCT04483739Phase 3Active Not Recruiting

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Role: collaborator

NCT04965155Phase 2Active Not Recruiting

A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)

Role: lead

All 4 trials loaded